Skip to Content

Treatment with Imatinib in Patients with Wild-Type GIST

In this MEDtalk, Louise Bjørn Larsen presents a study that sought to determine the benefit of imatinib in patients with wild-type GIST. The results show that the median PFS on first-line imatinib was 6 months in advanced wild-type GIST, but with great variability.

Louise Bjørn Larsen

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top